Capital Analysts LLC Has $12.65 Million Stake in Becton, Dickinson and Company $BDX

Capital Analysts LLC raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 7.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 83,601 shares of the medical instruments supplier’s stock after acquiring an additional 5,828 shares during the period. Capital Analysts LLC’s holdings in Becton, Dickinson and Company were worth $12,651,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Brighton Jones LLC boosted its position in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares in the last quarter. Empowered Funds LLC increased its holdings in shares of Becton, Dickinson and Company by 20.4% during the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after buying an additional 1,354 shares in the last quarter. United Bank raised its stake in shares of Becton, Dickinson and Company by 23.9% in the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock valued at $887,000 after acquiring an additional 993 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Becton, Dickinson and Company by 365.1% in the 2nd quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock worth $5,491,000 after acquiring an additional 25,022 shares in the last quarter. Finally, NewEdge Advisors LLC grew its position in Becton, Dickinson and Company by 34.7% during the 2nd quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock worth $4,048,000 after acquiring an additional 6,058 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

BDX has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Royal Bank Of Canada lifted their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a report on Thursday, August 13th. Bank of America increased their price objective on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, August 31st. Piper Sandler upped their target price on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Finally, Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $187.67.

Insider Activity

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 8,005 shares of company stock valued at $1,423,580. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Price Performance

Shares of BDX stock opened at $179.35 on Wednesday. The firm has a market cap of $49.42 billion, a price-to-earnings ratio of 54.02, a PEG ratio of 13.02 and a beta of 0.21. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $193.07. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The stock has a 50-day moving average price of $171.21 and a 200 day moving average price of $160.61.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the firm earned $3.68 EPS. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

About Becton, Dickinson and Company

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells medical devices, diagnostic products and laboratory equipment. Its offerings support healthcare providers, researchers, pharmaceutical manufacturers and patients across areas such as medication delivery, infection prevention, specimen collection, surgery and disease diagnosis.

BD’s products include needles, syringes, catheters, infusion and medication-management systems, injection devices, blood-collection products, diagnostic testing platforms, laboratory automation equipment and flow cytometry systems.